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Analysis of Published Criteria for Clinically Inactive
Disease in a Large Juvenile Dermatomyositis Cohort
Shows That Skin Disease Is Underestimated
Beverley Almeida,1 Raquel Campanilho-Marques,1 Katie Arnold,2 Clarissa A. Pilkington,3
Lucy R. Wedderburn,4 and Kiran Nistala,2 on behalf of
the Juvenile Dermatomyositis Research Group
Objective. The Pediatric Rheumatology Interna-
tional Trials Organisation (PRINTO) recently published
criteria for classification of patients with juvenile derma-
tomyositis (DM) as having clinically inactive disease.
The criteria require that at least 3 of 4 conditions be
met, i.e., creatine kinase level £150 units/liter, Child-
hood Myositis Assessment Scale score ‡48, Manual
Muscle Testing in 8 muscles score ‡78, and physician’s
global assessment of overall disease activity (PGA) £0.2.
The present study was undertaken to test these criteria
in a UK cohort of patients with juvenile DM.
Methods. We assessed 1,114 patient visits for the
4 items in the PRINTO criteria for clinically inactive
disease. Each visit was analyzed to determine whether
skin disease was present. The Disease Activity Score
(DAS) for juvenile DM was determined in 59 patients.
Results. At 307 of the 1,114 visits, clinically inac-
tive disease was achieved based on the 3 muscle criteria
(but with a PGA of >0.2); rash was present at 65.8%
of these visits and nailfold capillary abnormalities at
35.2%.When PGA£0.2 was one of the 3 criteria that were
met, the frequency of skin signs was significantly lower
(rash in 23.1% and nailfold capillary abnormalities in
8.7%). If PGA was considered an essential criterion for
clinically inactive disease (P-CID), patients with active
skin disease were less likely to be categorized as having
clinically inactive disease (a median DAS skin score of 0
[of a possible maximum of 9] in visits where the PGA was
£0.2, versus a median DAS skin score of 4 in patients
meeting the 3 muscle criteria [with a PGA of >0.2];
P < 0.001). Use of the P-CID led to improvements in the
positive predictive value and the positive likelihood ratio
(85.4% and 11.0, respectively, compared to 72.9% and 5.1
with the current criteria).
Conclusion. There was a high frequency of skin
disease among patients with juvenile DM who did not
meet the PGA criterion for inactive disease but met the
other 3 criteria. Incorporating PGA as an essential cri-
terion for clinically inactive disease helps prevent the
misclassification of patients with active skin disease.
Juvenile dermatomyositis (DM) affects approxi-
mately 2–3 children/million/year, and although rare, is
the most common childhood form of idiopathic inflam-
matory myopathy (1,2). Scoring tools have been devel-
oped to assess disease activity and damage in juvenile
DM in a standardized manner (3), to assist in the conduct
of clinical trials and allow comparisons between different
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cohorts. The Pediatric Rheumatology International
Trials Organisation (PRINTO) recently analyzed these
activity measures and defined thresholds for classification
of clinically inactive disease (4). Disease was considered
clinically inactive if the patient met at least 3 of 4 criteria,
i.e., creatine kinase (CK) level #150 units/liter, Child-
hood Myositis Assessment Scale (CMAS) score (5) $48,
Manual Muscle Testing in 8 muscles (MMT-8) score (6)
$78, and physician’s global assessment of overall disease
activity (PGA)#0.2.
These criteria are currently weighted toward mus-
cle disease. Although muscle symptoms are the main
focus of monitoring and treatment in juvenile DM, it is
important that skin inflammation is not neglected. Skin
disease is often resistant to treatment and may be associ-
ated with poor long-term outcomes such as calcinosis
(7,8), poor quality of life, and reduced physical function
(9,10). Therefore, we propose that skin disease should be
represented in any definition of clinically inactive disease.
At present, a patient with juvenile DM must meet only 3
of 4 criteria to be classified as having clinically inactive dis-
ease. Therefore, if all 3 muscle criteria are met, the PGA
may be disregarded. This poses the potential risk that dis-
ease activity in the skin or other organs will be ignored.
The purpose of this study was to apply the PRINTO crite-
ria for clinically inactive disease to a UK cohort of
patients with juvenile DM and test the hypothesis that in
clinical practice, there may be alternative definitions that
would improve the performance of the criteria.
PATIENTS AND METHODS
Patients. The study population consisted of patients
from the UK Juvenile Dermatomyositis Cohort and Bio-
marker Study (11); 1,114 discrete visits involving 258 patients
were analyzed. Written informed consent was obtained from
the legal guardians of all patients. All patients met the Bohan
and Peter criteria for diagnosis of juvenile DM (12,13); 74.6%
were female and 80.9% were white. The mean6 SD age at the
time of the visit assessed for the present study was 11.96 3.6
years. The mean age at diagnosis was 6.76 3.4 years, and the
mean disease duration was 4.46 3.1 years.
Data collection. Patient clinical data were collected at
the time of recruitment and then prospectively every 3–4 months
for the first 2 years and subsequently, at least once a year. Data
collected included signs and symptoms and disease activity meas-
ures: CMAS, MMT-8, PGA, and laboratory tests. Data related to
skin disease (rash, Gottron’s papules, ulceration, nailfold changes,
calcinosis) were retrieved for all patient visits. All data for the UK
Juvenile Dermatomyositis Cohort and Biomarker Study are stored
in a Structured Query Language platform database with Access
front-end data retrieval. Research coordinators and principal
investigators at the local study centers are listed in Appendix A.
Fifty-nine of the patients were clinically assessed using
the Disease Activity Score (DAS) for juvenile DM instrument
(14). The DAS was determined by 1 of 2 physicians (BA and
RC-M) at the time of clinical assessment of the patient. The
DAS instrument consists of 6 components, resulting in a 20-
point scale, with higher scores indicating greater disease activ-
ity. It has 2 subsections, the DAS muscle score (scored 0–11)
addressing functional status and the presence or absence of
weakness, and the DAS skin score (scored 0–9) related to skin
disease including skin involvement type, distribution, vasculi-
tis, and Gottron’s papules. For the purposes of the present
study, the DAS instrument was applied in its entirety (score
0–20), and separated into its muscle and skin subsections.
Data analysis. Patient visits were included in the study
if data on all 4 of the PRINTO criteria for clinically inactive dis-
ease (4) were available. Clinically inactive disease could be desig-
nated if all 4 criteria were met or if only 3 of the 4 were met. On
this basis, patient visits were divided into groups (Table 1).
Statistical analysis. Normally distributed continuous
variables were reported as the mean6SD, and non-normally
distributed continuous variables as the median and range.
Categorical data were analyzed by chi-square test. One-way
analysis of variance (ANOVA) with Tukey’s correction for
multiple testing was used to test the significance of differences
in DAS scores between groups. P values less than 0.05 were
considered significant.
Using diagnostic statistics, we compared the perform-
ance of the original criteria against “P-CID,” an alternative
definition of clinically inactive disease in which PGA is re-
garded as an essential criterion together with either 2 of the 3
muscle criteria. From the original cohort of 1,114 patient visits,
both definitions of clinically inactive disease were tested using
Table 1. Juvenile DM groups according to disease activity and PRINTO criteria met*
Group Disease status
No. of
PRINTO
criteria met PGA Other criteria
I Clinically inactive 4 Met (score #0.2) All met
II Clinically inactive 3 Met (score #0.2) Either CK or CMAS or MMT-8
not met
III Clinically inactive 3 Not met (score .0.2) CK, CMAS, and MMT-8 all met
IV Active 0 or 1 NA NA
* PRINTO criteria5Pediatric Rheumatology International Trials Organisation criteria for clinically
inactive juvenile dermatomyositis (DM); PGA5 physician’s global assessment of overall disease activity;
CK5 creatine kinase; CMAS5Childhood Myositis Assessment Scale; MMT-85Manual Muscle Test-
ing in 8 muscles; NA5not applicable.
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a reference group of patient visits: those occurring within 4
months of diagnosis and with the patient receiving medication
(active), and those occurring when the patient had not received
any medication for $6 months (inactive, or clinical remission as
defined by the International Myositis Assessment and Clinical
Studies Group consensus guidelines [15]). The time frame of 4
months from diagnosis was used based on our assumption that
these patients would have active disease. In order to demonstrate
whether P-CID would improve the performance of the criteria
for clinically inactive disease, separate analyses including sensitiv-
ity, specificity, positive and negative predictive values, and posi-
tive and negative likelihood ratios (with corresponding 95%
confidence intervals) were performed.
Data were stored in a central Access database and
analyzed with Excel. GraphPad Prism version 5.00 for Win-
dows was used for statistical analyses.
RESULTS
Among our cohort of 1,114 visits in 258 patients
with juvenile DM, the criteria for clinically inactive dis-
ease were met at 665 visits (59.7%) (Figure 1). All 4 of
the criteria were met at 254 (38.2%) of these 665 visits
(in 119 patients) (group I), while 3 of the 4 criteria were
met at the remaining 411 visits (61.8%) (in 165 patients).
Of the visits at which only 3 of the criteria were met, the
PGA was #0.2 in 104 (group II), while at the remaining
307, disease was clinically inactive based on the 3 muscle
criteria, but the PGA was.0.2 (group III).
To test if each of the criteria were equally redun-
dant, the 411 visits were divided based on which of the
criteria for clinically inactive disease was not met. The
median CK value in the group with CK .150 units/liter
was 206 units/liter (Figure 2A), and values were ,400
units/liter in the majority of outliers (range 152–650).
CMAS scores in the group not meeting the CMAS
threshold were clustered about a median value of 45,
although values of 28 and 34 were noted in the case of 2
outliers (Figure 2B). For patient visits not meeting the
MMT-8 threshold, scores were clustered close to 78
(median 73 [range 71–77]) (Figure 2C). However, for
PGA, unlike the findings for CK, CMAS, and MMT-8,
it was striking that the distribution of scores when the
PGA was .0.2 spanned the entire spectrum, from 0.3 to
8.5 (median 1.0) (Figure 2D).
Frequency of skin disease. In clinical practice,
the most common reason for ongoing juvenile DM dis-
ease activity in the setting of normal muscle results is skin
inflammation. To address this, the frequency of skin signs
was analyzed according to which of the specific criteria
for clinically inactive disease were met (Table 2). It is
generally thought by clinicians that a PGA score of .1.0
represents active disease. Of the visits in group III, the
PGA was .1.0 in 44% despite all of the muscle-related
criteria being met, suggesting the presence of ongoing
disease activity that did not involve muscles.
In group I (meeting all 4 of the criteria), skin signs
were still present, with rash observed in almost 30% and
nailfold abnormalities in 11% of the visits. Group II had
no significant differences in skin abnormalities when
compared to group I. In group III, the frequencies of
Figure 1. Flow chart of 1,114 visits among 258 patients from the UK Juvenile Dermatomyositis Cohort and Biomarker Study, according to the
Pediatric Rheumatology International Trials Organisation (PRINTO) criteria for clinically inactive disease. PGA5 physician’s global assessment
of overall disease activity; CK5 creatine kinase; CMAS5Childhood Myositis Assessment Scale; MMT-85Manual Muscle Testing in 8 muscles.
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skin signs were much higher and the data closely paral-
leled results in group IV. In group III (the PGA criterion
not met), the frequency of skin signs (except for ulcera-
tion) was significantly increased compared to group II
(for rash, x25 57.28, P , 0.0001; for Gottron’s papules,
x25 30.74, P , 0.0001; for nailfold changes, x25 26.84,
P , 0.0001; for calcinosis, x25 10.93, P5 0.0009). There
were no significant differences in the frequency of
ulceration.
Scores on the DAS for juvenile DM. Our results
suggested that PGA was an important criterion since it
identified ongoing skin disease. To confirm this hypothe-
sis, we used the DAS (14) to perform a detailed analysis of
muscle and skin disease in 59 of the patients with juvenile
DM. As expected, DAS total scores were low in group I
(median 0 [range 0–2]) (Figure 3A), suggesting that the
combined criteria successfully excluded patients with
active disease. There was no significant increase in DAS
total scores when group II (median 1 [range 0–6]) was
compared to group I (the reference group). However, the
DAS total score in group III was significantly increased
(median 5 [range 2–9]; P, 0.01 by ANOVA).
Figure 2. Analysis of disease activity and laboratory results in the 411 patient visits at which 3 of the 4 criteria for clinically inactive disease
were met. Each panel shows data analyzed when 1 of the 4 criteria was not met (i.e., CK in A, CMAS in B, MMT-8 in C, and PGA in D). Each
symbol represents an individual visit; horizontal lines show the median. See Figure 1 for definitions.
Table 2. Frequency of skin signs in patients with juvenile DM meeting the PRINTO criteria for clinically inactive disease*
Rash Gottron’s papules Ulceration Nailfold changes Calcinosis
Group I (254 visits, 118 patients) 76 (29.9) 32 (12.6) 1 (0.4) 28 (11.0) 19 (7.5)
Group II (104 visits, 70 patients) 24 (23.1) 11 (10.6) 1 (1.0) 9 (8.7) 6 (5.8)
Group III (307 visits, 131 patients) 202 (65.8) 123 (40.1) 9 (2.9) 108 (35.2) 60 (19.5)
Group IV (208 visits, 127 patients) 159 (76.4) 117 (56.3) 26 (12.5) 100 (48.1) 36 (17.3)
x2 (P)
Group I vs. group II 1.71 (NS) 0.29 (NS) 0.43 (NS) 0.45 (NS) 0.33 (NS)
Group I vs. group III 71.57 (,0.0001) 52.44 (,0.0001) 5.11 (0.024) 44.16 (,0.0001) 16.72 (0.0009)
Group II vs. group III 57.28 (,0.0001) 30.74 (,0.0001) 1.27 (NS) 26.84 (,0.0001) 10.93 (0.0009)
* See Table 1 for description of groups I, II, III, and IV. Values are the number (%) of visits. NS5 not significant (see Table 1 for other
definitions).
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To further explore the role of PGA within the set
of criteria for clinically inactive disease, we reanalyzed
the above data after separating the DAS total score into
its skin and muscle subsections. The DAS skin score
(Figure 3B) mirrored the DAS total score in that there
were no significant differences between group I (median
0 [range 0–2]) and group II (median 0 [range 0–4]).
DAS skin scores in group III (median 4 [range 1–7])
were significantly worse than those in groups I and II.
For the DAS muscle score, in contrast, there were no
significant differences in between groups I, II, and III
(median 0 in all 3 groups) (Figure 3C), confirming that
there was almost no active muscle disease.
Diagnostic performance of revised criteria. The
above results suggest that an increased PGA in the con-
text of normal muscle findings identifies patients with
juvenile DM who have ongoing skin inflammation. As
the P-CID appeared more stringent than the original
PRINTO criteria (Table 2), we wondered if this would
reduce its diagnostic utility. We thus compared the per-
formance of the original criteria against the P-CID (i.e.,
with PGA #0.2 as an essential criterion, together with
either 2 or 3 of the muscle-related criteria). Both defini-
tions of clinically inactive disease were tested, using the
originally identified 1,114 patient visits, to create 2 refer-
ence groups: 1) active disease (defined as patients who
had been diagnosed #4 months previously and were tak-
ing medication) (total 111 visits), and 2) inactive disease
(defined as patients who had not been taking medications
for$6 months) (total 59 visits).
We applied the PRINTO criteria to these 2
groups and classified the patient visits according to the
number of criteria met. Among the 111 visits at which the
disease was classified as active based on a duration of #4
months since diagnosis, 20 met the PRINTO criteria for
clinically inactive disease. In 13 of the 20 visits, the PGA
was.0.2 (3 criteria met); at 2 visits the PGA was#0.2 (3
criteria met), and all 4 of the criteria were met in 5 visits.
Among the 59 visits at which the disease was classified as
inactive based on a period of$6 months since treatment,
54 met the PRINTO criteria for clinically inactive dis-
ease. At 13 of these 54 visits the PGA was .0.2 (3 crite-
ria); at 11 visits the PGA was #0.2 (3 criteria), and all 4
of the criteria were met in 30 visits.
Figure 3. Scores according to the Disease Activity Score (DAS) for juvenile dermatomyositis in 59 patients meeting criteria for clinically inactive
disease. DAS total score (A), DAS skin score (B), and DAS muscle score (C) in patients who met all 4 criteria for clinically inactive disease
(group I), patients who met 3 of the 4 criteria, including the physician’s global assessment (PGA) #0.2 criterion (group II), patients who met 3
of the 4 criteria but not including the PGA #0.2 criterion (group III), and patients who met 0 or 1 of the criteria (active disease [group IV]) are
shown. Each symbol represents an individual patient; horizontal lines show the median. *5P , 0.05; ***5P , 0.001.
Table 3. Performance characteristics of the current (PRINTO) and revised criteria for clinically inac-
tive juvenile DM*
Current
criteria 95% CI
Alternative
definition of
clinically inactive
disease (P-CID) 95% CI
Sensitivity, % 91.5 80.5–96.8 69.5 56.0–80.5
Specificity, % 81.9 73.3–88.3 93.7 87.0–97.2
PPV, % 72.9 61.1–82.3 85.4 71.6–93.5
NPV, % 94.8 87.7–98.0 85.2 77.4–90.8
PLR 5.1 3.4–7.6 11.0 5.3–23.0
NLR 0.1 0.04–0.2 0.3 0.2–0.5
* 95% CI5 95% confidence interval; PPV5 positive predictive value; NPV5 negative predictive value;
PLR5 positive likelihood ratio; NLR5 negative likelihood ratio; P-CID5 clinically inactive disease
when the PGA criterion is met (see Table 1 for other definitions).
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Consequently, we calculated sensitivity, specificity,
positive and negative predictive values, and positive and
negative likelihood ratios based on the current PRINTO
criteria and the P-CID (Table 3). Compared to the cur-
rent criteria, the use of the P-CID led to an improvement
in the positive predictive value (85.4% versus 72.9%) and
positive likelihood ratio (11.0 versus 5.1), without an
appreciable deterioration in the negative predictive value
or negative likelihood ratio. Specificity also increased, to
93.7% (compared to 81.9% with the current criteria);
however, sensitivity of the P-CID was lower than that of
the current criteria (69.5% versus 91.5%).
DISCUSSION
Many patients with juvenile DM have prolonged
disease courses and require long-term treatment. It is
therefore important to be able to accurately define clini-
cally inactive disease in order to aid in assessment of
their condition and guide treatment decisions. To this
end, PRINTO has proposed a set of criteria for clini-
cally inactive disease in juvenile DM, which are based
on disease activity measures that are in routine clinical
use. In the present study we formally tested these crite-
ria in a large independent cohort of patients with juve-
nile DM and investigated whether they performed
adequately in a real-world clinical setting.
Based on the PRINTO criteria, the definition of
clinically inactive disease was met at nearly 60% of our
patient visits. As 3 of the 4 PRINTO measures are
specific to muscle disease, we wondered if there was
redundancy between these items. Indeed, we found that
omission of 1 of the 3 muscle criteria had little impact
on the disease activity scores in that domain. In contrast,
during visits at which patients met the 3 muscle criteria
but not the PGA criterion, PGA scores were increased,
despite normal muscle findings. Our results identified a
subset of patients, with high PGA scores but normal
muscle findings, who exhibited a high frequency of skin
abnormalities. We predicted that these patients had
active skin disease, but as our longitudinal cohort study
data could not easily distinguish between damage and
active disease (e.g., atrophic Gottron’s papules), we pro-
spectively assessed 59 patients using the DAS for juve-
nile DM. In this carefully characterized patient cohort,
it was clear that patients in group III had significantly
higher DAS skin scores than patients in group I or II,
confirming that use of muscle criteria alone failed to
identify patients with active skin disease.
Although the majority of the DAS instrument
specifically identifies clinical activity, a few of the skin
items may detect damage (e.g., atrophic changes within
the skin involvement section of the instrument and tel-
angiectasia in the vasculitis section). However, when
these items were removed from the analysis, the results
were unchanged (data not shown).
Recently, investigators from Norway retrospec-
tively analyzed an inception cohort of 59 patients with
juvenile DM who had been followed up for a long period
of time (16). They found a rate of clinically inactive disease
of 49%, similar to our results. Only 48% of the Norwegian
patients meeting criteria for clinically inactive disease had
a normal score on the Myositis Intention-to-Treat Activity
Index (MITAX) (17), an instrument measuring disease
activity in 7 distinct organ domains. However, if the skin
domain was excluded from the MITAX, 87% of patients
meeting criteria for clinically inactive disease had a nor-
mal score. These results are consistent with our finding
that skin disease is underestimated with the use of the
PRINTO criteria for clinically inactive disease.
One limitation of our study is that we did not
have accurate data on disease activity in other organs.
Although we show that many patients with a high PGA
score in the setting of normal muscle results have active
skin disease, it is possible that the elevated PGA score
also relates to disease in other organs.
When compared to the existing PRINTO crite-
ria, the use of the P-CID improved the specificity and
the positive predictive value for clinically inactive dis-
ease but reduced sensitivity, suggesting that our modifi-
cation increased the stringency of the tool. In this
analysis we considered visits occurring within 4 months
of diagnosis to be representative of patients with clini-
cally active disease. However, this may underestimate
the specificity of tools for defining clinically inactive dis-
ease, as a small number of patients within this group
had no evidence of active disease and may reflect a sub-
set with a milder disease course or those who are early
responders to treatment.
We also considered the use of the PGA and
MMT-8 alone to define clinically inactive disease, but
this did not yield better results than our proposed P-CID.
However, such a 2-item instrument warrants considera-
tion in a further validation study examining criteria for
clinically inactive disease.
We therefore propose that the existing PRINTO
criteria for defining clinically inactive disease in patients
with juvenile DM require modification, either with the
use of the PGA as an essential criterion or by adding
items that specifically measure skin disease activity.
These modifications need to be tested in future studies,
and should ensure that active skin disease related to
juvenile DM is not overlooked in the definition of clini-
cally inactive disease.
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APPENDIX A: LOCAL PRINCIPAL INVESTIGATORS,
RESEARCH COORDINATORS, AND MEMBERS OF THE
JUVENILE DERMATOMYOSITIS RESEARCH GROUP
Contributing local research coordinators, principal investiga-
tors, and Juvenile Dermatomyositis Research Group members (all in
the UK except as indicated otherwise) were as follows: Dr. Kate
Armon, Ms Vanja Briggs, Mr. Joe Ellis-Gage, Ms Holly Roper, Ms
Joanna Watts (Norfolk and Norwich University Hospitals, Norwich);
Dr. Eileen Baildam, Ms Louise Hanna, Ms Olivia Lloyd, Dr. Liza
McCann, Mr. Ian Roberts (Royal Liverpool Children’s Hospital, Liv-
erpool); Ms Ann McGovern, Dr. Phil Riley (Royal Manchester
Children’s Hospital, Manchester); Dr. Eslam Al-Abadi, Dr. Clive
Ryder, Ms Janis Scott, Dr. Taunton Southwood, Ms Beverley Thomas
(Birmingham Children’s Hospital, Birmingham); Dr. Tania Amin, Ms
Deborah Burton, Ms Gillian Jackson, Dr. Vanessa Van Rooyen, Dr.
Mark Wood, Dr. Sue Wyatt (Leeds General Infirmary, Leeds); Mr.
Michael Browne, Dr. Joyce Davidson, Ms Sue Ferguson, Dr. Janet
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Gardner-Medwin, Dr. Neil Martin, Ms Liz Waxman (Royal Hospital
for Sick Children, Glasgow); Dr. Helen Foster, Dr. Mark Friswell,
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Ms Vicky Stevenson, Ms Alison Swift, Ms Debbie Wade, Mr. Stuart
Watson (Great North Children’s Hospital, Newcastle); Ms Lindsay
Crate, Ms Anna Frost, Ms Mary Jordan, Dr. Ellen Mosley, Dr. Ran-
garaj Satyapal, Ms Elizabeth Stretton, Dr. Helen Venning, Dr. Kish-
ore Warrier (Queens Medical Centre, Nottingham); Dr. Beverley
Almeida, Ms Katie Arnold, Ms Laura Beard, Ms Virginia Brown, Dr.
Raquel Campanilho-Marques, Ms Elli Enayat, Ms Yvonne Glackin,
Ms Elizabeth Halkon, Dr. Nathan Hasson, Ms Audrey Juggins, Ms
Laura Kassoumeri, Ms Sian Lunt, Ms Sue Maillard, Dr. Kiran Nis-
tala, Dr. Clarissa Pilkington, Ms Stephanie Simou, Dr. Sally Smith,
Ms Hemlata Varsani, Dr. Lucy Wedderburn (Great Ormond Street
Hospital, London); Dr. Kevin Murray (Princess Margaret Hospital,
Perth, Western Australia, Australia); Dr. John Ioannou, Ms Linda Suf-
field (University College London Hospital, London); Dr. Muthana Al-
Obaidi, Ms Sam Leach, Ms Helen Lee, Ms Helen Smith (Sheffield’s
Children’s Hospital, Sheffield); Ms Emma Inness, Ms Eunice Kendall,
Mr. David Mayers, Dr. Nick Wilkinson (Oxford University Hospitals,
Oxford); Dr. Jacqui Clinch, Ms Helen Pluess-Hall (Bristol Royal Hos-
pital for Children, Bristol).
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Clinical Images: Rapidly reversible winging scapula
The patient, a 46-year-old woman, presented with a 2-year history of painless weakness in facial and limb-girdle muscles, uncompli-
cated by cardiac or respiratory symptoms. She had 2 cousins with facioscapulohumeral muscular dystrophy (30-kb deletion in the
D4Z4 gene) diagnosed via classical and molecular methods. Physical examination revealed bilateral winging scapula (A), with bilat-
eral weakness in the serratus, trapezius, and deltoid (Medical Research Council [MRC] grade 2/5), the iliopsoas and quadriceps
(MRC grade 3/5), and the right orbicularis oculi (MRC grade 4/5), as well as Raynaud’s phenomenon. The creatine kinase (CK) level
was 4,720 IU/liter (normal ,150 IU/liter). Needle electromyography revealed myopathic changes with no spontaneous activity. No
deletions or hypomethylation in the D4ZA gene were found via molecular testing. Magnetic resonance imaging (MRI) of the muscles
showed bilateral hyperintensity in the deltoid, gluteus maximus, and pectineus, as well as in the right infraspinatus, on STIR sequen-
ces, revealing muscle edema (arrows in B). Biopsy of the right deltoid showed necrotizing myopathy, with negligible inflammatory
and fibrotic components (asterisk in C). An occult neoplasm was excluded, and a serologic test revealed positivity for anti-Ro (1:30)
and anti–signal recognition particle (anti-SRP) autoantibodies (1:640). Based on evidence of anti-SRP chronic immune myopathy,
the patient was treated on a quarterly basis with intravenous immunoglobulin (0.4 gm/kg for 5 days) and azathioprine. After 1 year of
followup, the limb-girdle muscle weakness recovered to 4–/5, the winging scapula began to disappear (D), findings on MRI of the
muscles dramatically improved (arrow in E), and levels of SRP antibodies and CK decreased (1:160 and 333 IU/liter, respectively).
Immune-mediated necrotizing myopathy associated with SRP antibodies causes severe subacute proximal muscle weakness and high
CK levels and has been linked to cardiac involvement (Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the
signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420–8). Infrequently, the course
can be chronic and can progress slowly, resembling muscular dystrophy and leading to a misdiagnosis and the loss of therapeutic
intervention (Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I. Myopathy associated with antibodies to signal
recognition particle: disease progression and neurological outcome. Arch Neurol 2012;69:728–32).
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